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ABSTRACT 
MicroPulse transscleral cyclophotocoagulation (IRIDEX Corp., Mountain View, CA) is a novel technique that uses 
repetitive micropulses of active diode laser (On cycles) interspersed with resting intervals (Off cycles). It has been 
proposed that the OFF cycles allow thermal dissipation and, therefore, reduce collateral damage. The literature suggests 
that Micropulse has a better safety profile compared to traditional continuous-wave cyclophotocoagulation. However, 
because it is a relatively new technique, there are no clear guidelines stating the ideal laser parameters that would allow 
the best balance between high and sustained effectiveness with minimal side effects. This research reviewed the 
literature to approximate ideal parameters for single-session treatment. To simplify the comparison between studies, 
this study used Joules (J) as a way to standardize the energy levels employed. The reviewed clinical publications allowed 
reduction of these parameters to a range between 112 and 150 J of total energy, which allows a moderate IOP lowering 
effect of around 30% with few/no complications. An additional narrowing of the parameters was achieved after 
analyzing recently published experimental data. These data suggest a different mechanism of action for the Micropulse, 
similar to that of the pilocarpine. This effect was maximum at 150 J. Since clinical studies show few or no complications, 
even at those energy levels, it could be hypothesized that the ideal parameters can be located at a point closer to 150 J. 
This data also leads to the concept of dosimetry; the capacity to dose mTSCPC treatment based on desired IOP lowering 
effect and risk exposure. Further prospective studies are needed to test the proposed evidence-based hypothesis. 
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INTRODUCTION
Glaucoma is one of the main causes of irreversible 
blindness, worldwide [1]. Historically, when hypotensive 
medical treatment or laser treatment of the trabecular 
meshwork (TM) were not enough to control the disease, 
traditional surgical procedures (e.g. filtering surgery, and 
drainage devices implantation) were contemplated. 
Unfortunately, they are not always effective and present 
a high incidence of complications of variable severity [2]. 
In recent years, a new group of surgical techniques, 
known as Minimally Invasive Glaucoma Surgeries (MIGS), 
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have been conceived to occupy a niche in the surgical 
treatment of mild to moderate glaucoma [3-8]. However, 
although usually safe, their effectiveness and long-term 
performance is yet to be fully established. Regardless, 
when all these surgical options are exhausted, 
transscleral cyclophotocoagulation with diode laser 
becomes an option [9]. It has been proposed that this 
technique decreases IOP by combining two mechanisms. 
The first mechanism is probably the photo-destruction of 
the ciliary body pigmented and non-pigmented 
epithelium (810 nanometer diode laser wavelength is 
better absorbed by melanin). The second mechanism is 
the increase in the aqueous humor drainage through the 
uveoscleral pathway [10]. With this technique, severe 
complications are frequently reported, including 
hypotony, phthisis bulbi, chronic inflammation, and 
decreased visual acuity [11-15]. 
Motivated by these limitations, a modified transscleral 
cyclophotocoagulation technique has been developed. 
The infrared MicroPulse® transscleral 
cyclophotocoagulation (IRIDEX Corp., Mountain View, 
CA) is a novel technique that uses repetitive micropulses 
of active diode laser (On cycles), interspersed with rest 
intervals (Off cycles) [16]. It has been proposed that the 
Off periods allow for thermal dissipation, and thus, 
reduce collateral damage and adverse effects [13]. 
Energy level (i.e. total time of treatment and power), 
area treated, positioning of the probe, and velocity of 
sweeping motion are all modifiable parameters that can 
influence the clinical outcome of this technique. At 
present, given its novelty, there are no clear guidelines 
on how to balance these parameters to achieve high 
effectiveness with minimal side effects. In this article, the 
researchers reviewed the literature and current evidence 
and developed a hypothesis, in an attempt to 
approximate the ideal parameters for this technique. 
METHODS 
A bibliographic search was performed using Pubmed, 
covering publications between years 2015 and 2018. A 
broad match combination of keywords was used, 
including glaucoma AND Micropulse. Twenty-eight 
papers were obtained. This research excluded studies 
that were not original articles, did not refer to glaucoma, 
did not employ the transscleral cyclophotocoagulation 
technique, were written in languages other than English, 
and those that did not describe the laser parameters 
employed. Finally, a total of nine papers remained 
eligible. The review was complemented using references 
of the cited studies, when appropriate. Finally, the 
researchers reviewed AGS abstracts, and ARVO abstracts 
published in Investigative Ophthalmology & Visual 
Science Journal (IOVS) during years 2017 and 2018 that 
were not published as papers; one of them being an 
experimental study (Johnstone et al, 2017). 
Micropulse versus Continuous Wave Transscleral 
Cyclophotocoagulation 
Micropulse is considered as equally effective yet safer 
than Continuous Wave Transscleral 
Cyclophotocoagulation (CW-TSCPC) [13]. Aquino et al. 
compared the efficacy and safety of Micropulse 
Transscleral Cyclophotocoagulation (mTSCPC) against 
CW-TSCPC. After 12 months of follow-up, the results 
showed that in the mTSCPC group, 75% of the cases (18 
of 24 patients) achieved the success criteria (IOP 
between 6 and 21 mmHg and at least 30% decrease in 
baseline IOP), against 29% (7 of 24 patients) in the CW-
TSCPC group (p<0.01). They reported that 46 of 48 
patients completed 18 months of follow-up. No 
significant difference in the success rate between the 
two treatments was observed; the results were 52% (n = 
12) for the Micropulse and 30% (n = 7) for the CW-TSCPC 
method (P = 0.13). The mean baseline IOP, at 18 months 
of follow-up, decreased by 45% in both groups (P = 0.70), 
from a baseline of 36.5mmHg (29.5 to 16.5) in the 
mTSCPC group and 35.0mmHg (29.5 to 46.5) in the CW-
TSCPC (P = 0.50). There were no significant differences in 
the IOP reduction between the two groups (P = 0.70). 
There were no significant differences in the need for 
retreatment (P = 0.36). There was also no difference in 
the decrease of IOP lowering medications (P = 0.88), this 
being two to one drug in both groups (P < 0.01). 
However, the complication rate was higher with the CW-
TSCPC method (P = 0.01). Prolonged hypotonia (IOP ≤ 
5mmHg for more than six months) was observed in five 
eyes treated with CW-TSCPC versus none in the 
MicroPulse group, visual acuity decrease was found in 9% 
(2/23) of the CW-TSCPC group versus 4% (1/23) in case of 
the mTSCPC, prolonged inflammation of the anterior 
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chamber was observed in 30% (7/23) versus 4% (1/23), 
phthisis bulbi 4% (1/23) versus 0%, and scleral thinning 
17% (4/23) versus 4% (1/23), respectively [13]. Similar 
results were observed in a comparative study between 
CW-TSCPC and mTSCPC, on 45 eyes of 36 pediatric 
patients. The success rate was higher in the mTSCPC 
group (71% versus 46% in the CW-TSCPC group) yet the 
difference was not significant (P = 0.1). No significant 
complications were noted in the mTSCPC group, whereas 
in the CW-TSCPC group, one eye developed phthisis bulbi 
and two eyes had severe pain and uveitis (P = 0.3) [17]. 
Mechanism of Action 
The mechanism of action of this technique is not yet fully 
elucidated. Traditional diode laser has a greater 
absorption in melanin-containing tissues [9, 18]. 
Although the adjacent non-pigmented tissues absorb less 
direct energy from the laser, they still exhibit collateral 
damage [18]. This occurs because it is impossible to avoid 
an indirect transfer of caloric energy from the targeted 
pigmented epithelium and dissipate it before reaching 
coagulation temperatures [19]. Clinical and experimental 
studies propose that the OFF periods in the Micropulse 
restrict the accumulation of caloric energy in the tissues 
adjacent to the pigmented epithelium. This allows 
thermal dissipation, preventing from reaching 
coagulation temperatures and, therefore, reducing 
collateral damage [16, 20, 21]. A second component for 
the mechanism of action, involving an increase in the 
aqueous humor drainage through the uveoscleral 
pathway, has also been reported [10]. A third mechanism 
of action for the Micropulse has recently been proposed 
by Johnstone [22] et al., after an experimental study on 
monkeys (m. Fascicularis) [22]. According to the authors, 
the pigmented epithelium is not necessarily involved in 
the mechanism of action. In contrast, Micropulse would 
actually act on the longitudinal fibers of the Ciliary 
muscle (CM), causing a displacement of the Scleral Spur 
(SS) in a posterior and inward direction, which in turn 
modifies the configuration of the TM and the outflow 
tract of the aqueous humor. This effect is similar to that 
of pilocarpine, which causes enlargement of the 
trabecular spaces and expansion of the Schlemm’s canal 
area, reducing the tendency towards collapse or 
narrowing of the canal lumen, thus, facilitating the 
drainage of aqueous humor [23]. It is difficult to conclude 
at this point if one of these suggested mechanisms of 
action has the most effect on IOP or whether the IOP 
lowering effect of this technique is in fact a combination 
of all mechanisms. 
Surgical Technique 
Laser treatment is applied over the 360 degrees of the 
eye, sparing -or not- the three and nine o’clock position. 
Some physicians opt for a fast-sweeping motion of about 
10 seconds back-and-forth over 180 degrees, others use 
a slow-sweeping motion of about one-minute over the 
same distance, or somewhat in between [24]. 
The probe has a notch that is oriented towards the 
central cornea and its base rests close to the conjunctival 
limbus or a few millimeters posterior. The current probe 
was designed to allow for precise positioning of the fiber-
optic tip at 3 mm posterior to the limbus [13, 16]. 
Ideal Parameters: where are we Standing? 
Despite promising initial results, the ideal parameters for 
the Micropulse, to obtain the best balance of 
efficacy/safety, have not yet been established. 
Nevertheless, at this point, the miscellaneous data 
currently available on the literature can help 
approximate these parameters. Due to considerable 
variability in laser settings within published studies, it is 
useful to convert the total energy used in each of the 
settings to Joules in order to facilitate interstudy 
comparison, as introduced by Murray Johnstone et al. in 
their experimental study [22]. Joules (J) = power in Watts 
(W) x total treatment duration in seconds (s) x ON cycle 
(31.3%). This would exclude other potential variables 
from the equation, such as velocity of sweeping motion 
and the positioning distance of the probe from the 
limbus. 
Fig 1 illustrates five representative studies that used 
different energy levels, mainly by varying treatment 
duration. Continuous, warm-colored lines represent 
higher energy levels (200 to 225 J), while green is for 
mid-range levels (112 to 140 J) and cold colors are for 
low-energy levels (≤100J). It is possible to infer a positive 
relationship between total energy and IOP decrease. 
Williams et al. [25] and Emanuel et al. [24] used up to 
200 J and 225 J of energy (320 and 360s x 2W x 31.3% ON 
cycle) and obtained an IOP decrease from baseline of 
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46% and 60%, respectively. However, complications 
soared to more than 45% in both studies (dashed lines 
represent complications). Persistent hypotonia, 
postoperative inflammation >3 months, and loss of 2+ 
Snellen lines were the most common. Indeed, the upper 
level of total energy that can be applied is mainly limited 
by the emergence of complications. There are a few 
reports that applied mid-range energy levels of around 
112 to 140 J (180s x 2 to 2.5W and 31.3% ON cycle). They 
obtained a moderate IOP decrease of approximately 
30%, without complications [26-28] for at least 12 
months. Other studies that used relatively low energy 
levels, ≤100 J (≤ 160s x 2W x 31.3 ON cycle), were 
moderately effective (around 30% IOP decrease) in the 
short-term (~1 month) without complications, yet in 
many cases, more than one laser session (up to three) 
was required to maintain the effect in the mid-term [18, 
28, 29], leading some authors to abandon them for 
insufficient results [25]. The study by Sanchez FG et al. 
was in concordance with the literature [30]. The 
researchers applied energy levels within the 62 to 112 J 
range (varying only the treatment duration, power fixed 
at 2W, and ON cycle at 31.3%) on 22 eyes of 17 patients 
(mostly congenital and pseudoexfoliation types), with 
over six months of follow-up with only one treatment 
session per eye. Overall success was low (27.3%). 
However, patients treated with higher energy levels (112 
J) obtained up to 75% success and an IOP decrease from 
baseline of 34%. All patients that received the lowest 
energy level (62 J) failed. No complications were 
observed in any of the cases. Taken together, all these 
clinical data indicate a good balance of efficacy/safety, 
ranging from 112 to 150 J, allowing a moderate IOP 
decrease of about 30% with few/no complications. From 
this point on, the data of clinical origin do not allow 
further approximation of the ideal parameters for the 
mTSCPC. Fortunately, the very interesting experimental 
work in enucleated m. Fascicularis eyes presented by 
Johnstone et al. [22] provides key data with untapped 
potential that may help better understand the clinical 
evidence so far. As it was previously described under 
‘mechanism of action’, the authors propose a 
pilocarpine-like effect for the Micropulse as its main 
mechanism of action, rather than photocoagulation of 
the pigmented ciliary epithelium. Therefore, they 
designed the experiment to evaluate recoil/relaxation in 
the pre-treatment state of the CM, SS, and TM, after 
different levels of total energy was delivered with the 
mTSCPC. Fig 2 shows the recovery percentage (y-axis) 
observed in their experiment with increasing total energy 
in Joules (x-axis). An equivalent of Joules expressed in 
seconds x power was added to facilitate the 
interpretation. 
Figure 1: Clinical Outcomes with Variable Energy Levels.  X-axis: Follow-up Time. Continuous Lines on Y-axis: IOP Decrease. Secondary Axis (Dashed 
Lines): Complications (%). Warm, Green and Cold Colors Represent High, Medium and Low Energy Levels, Respectively. Abbreviations: J: Joules. 
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Figure 2: Experimental and Clinical Data Overlap. X-axis shows Increasing Energy Levels in Joules. Blue Bars on the Y-axis Summarizes the Progressively 
Less Recoil/Relaxation of SS, CM, and TM observed in the Experimental Study (Johnstone et al). Secondary axis represents Clinical Complications with 
Increasing Energy Levels Reported in the Literature. The Colored Bar Illustrates Evidence-based Hypothesis of the Best Balance Efficacy/Safety. 
Abbreviations: J: Joules; W: Watts; CM: Ciliary Muscle; SS: Scleral Spur; TM: Trabecular Meshwork. 
 
An almost complete recovery/relaxation (i.e. complete 
loss of the pilocarpine-like effect) was observed at lower 
energy levels of less than 62 J (equivalent to a laser 
setting of 100s x 2W x 31.3% ON cycle). Progressively less 
recovery was observed as more energy was applied. 
Above a considerably higher energy level (150 J), no 
recovery was observed (i.e. full permanence of the 
effect). This is equivalent to a laser setting of 240s x 2W x 
31.3% ON cycle. Superimposed is a red dotted line 
representing the emergence of adverse effects reported 
so far in clinical studies. A colored bar was added, 
summarizing the clinical results with different energy 
levels in the literature. The experimental data suggests 
that the pilocarpine-like effect explains at least part of 
the clinical response observed with different energy 
levels. Based on this, to fully benefit from this 
mechanism, the energy level should be increased to 
nearly 150 J (equivalent to 240s x 2W x 31,3%) [22]. 
Beyond 150 J, significant side effects start to appear, 
while no additional pilocarpine-like effect is added. Taken 
together, the clinical and experimental results suggest a 
sweet spot between 112 to 150 J. When the clinical and 
the experimental results are combined, it is possible to 
redefine the sweet spot more precisely at energy levels 
closer to 150 J to maximize the pilocarpine-like effect. In 
this way, with energy levels closer to 150 J, maximum 
benefit could be obtained from the combination of the 
multiple mechanisms of action proposed for the 
Micropulse, without triggering the complication rate. 
Although above 200 J the percentage of IOP reduction is 
greater (approximately 40% to 60% from baseline), 
moderate to severe complications increase considerably 
[24, 25]. A possible explanation may be that the extra IOP 
lowering effect mainly depends, at this level, on 
cyclodestruction. 
Re-treatment 
When it comes to using this new therapeutic technology, 
two surgical approaches are possible. One treatment is 
described above with the expectation of achieving 
success or the possibility of repeated treatments with 
lower energy levels to achieve target pressure. There is 
little published evidence on re-treatments. Aquino et al. 
[13] and Tan et al. [16] used shorter treatment durations 
of 100s x 2W (62.5J), yet performed a second or a third 
session when the first session had failed. From a total of 
23 patients treated with the Micropulse, Aquino et al. 
needed to re-treat 11 patients (48%), whose IOP 
remained uncontrolled after a mean of 6.8 months 
(range two to 17 months). They performed a second 
session on seven patients and a third session on four. 
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Even after the third session, those four eyes (all 
neovascular glaucomas) failed again.  
Comparably, Tan et al. needed to re-treat 14 out of 40 
eyes (35%). From those 14 eyes, nine failed again after 
the second treatment yet did not undergo a third 
session. No significant complications were observed in 
any of the studies. 
Increased Risk in Certain Populations 
Radhakrishnan et al. reported higher odds of persistent 
mydriasis in the Asian race (OR 13.07, P < 0.001) and 
phakic status (OR 3.12, P = 0.014) in a 144-patient cohort 
[31]. Williams et al. stated that it is reasonable to use 
shorter treatment times in heavily pigmented patients 
with the understanding that repeat treatment may be 
needed later, should this initial approach be ineffective, 
and considering the significantly higher odds of 
prolonged inflammation found in this population (OR 
3.61, 95% CI 1.27-10.23; P = 0.02). In patients with good 
vision at baseline (given the non-infrequent incidence of 
vision loss in their study), 13 patients showed loss of 2+ 
lines of best-corrected visual acuity for ≥ 3 months 
(16.5%) [25]. Individualizing treatments based on 
patients and disease characteristics is the next step in the 
ongoing development of this technology.  
CONCLUSION 
The available data, although scarce and difficult to 
compare because of varying definitions of success criteria 
and use of laser parameters, suggest that a good balance 
of efficacy/safety can be narrowed to an intermediate 
amount of total energy of approximately 112 to 150 J. 
This would allow an adequate IOP decrease with few/no 
complications, opening the possibility and initial rationale 
to dose the treatment based on desired IOP lowering 
effect and risk exposure. Prospective comparative 
studies, with homogeneous success criteria definitions 
and longer follow-up periods, are necessary to precisely 
determine Micropulse’s ideal parameters, especially 
evaluating the individual characteristics of each patient 
and their glaucoma. It would be interesting to also 
evaluate the impact of re-treatment, probe motion 
velocity, and probe positioning on clinical outcomes. 
 
 
DISCLOSURE 
Ethical issues have been completely observed by the 
authors. All named authors meet the International 
Committee of Medical Journal Editors (ICMJE) criteria for 
authorship of this manuscript, take responsibility for the 
integrity of the work as a whole, and have given final 
approval for the version to be published. No conflict of 
interest has been presented. 
REFERENCES 
1. Quigley HA, Broman AT. The number of people with 
glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 
2006;90(3):262-7. doi: 10.1136/bjo.2005.081224 pmid: 
16488940 
2. Gedde SJ, Schiffman JC, Feuer WJ, Herndon LW, Brandt JD, 
Budenz DL, et al. Treatment outcomes in the Tube Versus 
Trabeculectomy (TVT) study after five years of follow-up. 
Am J Ophthalmol. 2012;153(5):789-803 e2. doi: 
10.1016/j.ajo.2011.10.026 pmid: 22245458 
3. Spiegel D, Garcia-Feijoo J, Garcia-Sanchez J, Lamielle H. 
Coexistent primary open-angle glaucoma and cataract: 
preliminary analysis of treatment by cataract surgery and 
the iStent trabecular micro-bypass stent. Adv Ther. 
2008;25(5):453-64. doi: 10.1007/s12325-008-0062-6 pmid: 
18594784 
4. Patel I, de Klerk TA, Au L. Manchester iStent study: early 
results from a prospective UK case series. Clin Exp 
Ophthalmol. 2013;41(7):648-52. doi: 10.1111/ceo.12098 
pmid: 23448425 
5. Arriola-Villalobos P, Martinez-de-la-Casa JM, Diaz-Valle D, 
Fernandez-Perez C, Garcia-Sanchez J, Garcia-Feijoo J. 
Combined iStent trabecular micro-bypass stent 
implantation and phacoemulsification for coexistent open-
angle glaucoma and cataract: a long-term study. Br J 
Ophthalmol. 2012;96(5):645-9. doi: 10.1136/bjophthalmol-
2011-300218 pmid: 22275344 
6. Neuhann TH. Trabecular micro-bypass stent implantation 
during small-incision cataract surgery for open-angle 
glaucoma or ocular hypertension: Long-term results. J 
Cataract Refract Surg. 2015;41(12):2664-71. doi: 
10.1016/j.jcrs.2015.06.032 pmid: 26796447 
7. Samuelson TW, Katz LJ, Wells JM, Duh YJ, Giamporcaro JE, 
Group USiS. Randomized evaluation of the trabecular 
micro-bypass stent with phacoemulsification in patients 
with glaucoma and cataract. Ophthalmology. 
2011;118(3):459-67. doi: 10.1016/j.ophtha.2010.07.007 
pmid: 20828829 
8. Malvankar-Mehta MS, Chen YN, Iordanous Y, Wang WW, 
Costella J, Hutnik CM. iStent as a Solo Procedure for 
Glaucoma Patients: A Systematic Review and Meta-
Analysis. PLoS One. 2015;10(5):e0128146. doi: 
10.1371/journal.pone.0128146 pmid: 26018579 
9. Pastor SA, Singh K, Lee DA, Juzych MS, Lin SC, Netland PA, 
et al. Cyclophotocoagulation: a report by the American 
 
 
Med Hypothesis Discov Innov Ophthalmol. 2018; 7(3)  
 
100 
 
MICROPULSE TRANSSCLERAL CYCLOPHOTOCOAGULATION 
Academy of Ophthalmology. Ophthalmology. 
2001;108(11):2130-8. pmid: 11713091 
10. Liu GJ, Mizukawa A, Okisaka S. Mechanism of intraocular 
pressure decrease after contact transscleral continuous-
wave Nd:YAG laser cyclophotocoagulation. Ophthalmic Res. 
1994;26(2):65-79. doi: 10.1159/000267395 pmid: 8196935 
11. Kosoko O, Gaasterland DE, Pollack IP, Enger CL. Long-term 
outcome of initial ciliary ablation with contact diode laser 
transscleral cyclophotocoagulation for severe glaucoma. 
The Diode Laser Ciliary Ablation Study Group. 
Ophthalmology. 1996;103(8):1294-302. pmid: 8764801 
12. Mistlberger A, Liebmann JM, Tschiderer H, Ritch R, 
Ruckhofer J, Grabner G. Diode laser transscleral 
cyclophotocoagulation for refractory glaucoma. J 
Glaucoma. 2001;10(4):288-93. pmid: 11558813 
13. Aquino MC, Barton K, Tan AM, Sng C, Li X, Loon SC, et al. 
Micropulse versus continuous wave transscleral diode 
cyclophotocoagulation in refractory glaucoma: a 
randomized exploratory study. Clin Exp Ophthalmol. 
2015;43(1):40-6. doi: 10.1111/ceo.12360 pmid: 24811050 
14. Bloom PA, Tsai JC, Sharma K, Miller MH, Rice NS, Hitchings 
RA, et al. "Cyclodiode". Trans-scleral diode laser 
cyclophotocoagulation in the treatment of advanced 
refractory glaucoma. Ophthalmology. 1997;104(9):1508-19; 
discussion 19-20. pmid: 9307649 
15. Quigley HA. Improved Outcomes for Transscleral 
Cyclophotocoagulation Through Optimized Treatment 
Parameters. J Glaucoma. 2018;27(8):674-81. doi: 
10.1097/IJG.0000000000001008 pmid: 29916995 
16. Tan AM, Chockalingam M, Aquino MC, Lim ZI, See JL, Chew 
PT. Micropulse transscleral diode laser 
cyclophotocoagulation in the treatment of refractory 
glaucoma. Clin Exp Ophthalmol. 2010;38(3):266-72. doi: 
10.1111/j.1442-9071.2010.02238.x pmid: 20447122 
17. Abdelrahman AM, El Sayed YM. Micropulse Versus 
Continuous Wave Transscleral Cyclophotocoagulation in 
Refractory Pediatric Glaucoma. J Glaucoma. 
2018;27(10):900-5. doi: 10.1097/IJG.0000000000001053 
pmid: 30113515 
18. Pantcheva MB, Kahook MY, Schuman JS, Noecker RJ. 
Comparison of acute structural and histopathological 
changes in human autopsy eyes after endoscopic 
cyclophotocoagulation and trans-scleral 
cyclophotocoagulation. Br J Ophthalmol. 2007;91(2):248-
52. doi: 10.1136/bjo.2006.103580 pmid: 16987899 
19. Feldman RM, el-Harazi SM, LoRusso FJ, McCash C, Lloyd 
WC, 3rd, Warner PA. Histopathologic findings following 
contact transscleral semiconductor diode laser 
cyclophotocoagulation in a human eye. J Glaucoma. 
1997;6(2):139-40. pmid: 9098823 
20. Desmettre TJ, Mordon SR, Buzawa DM, Mainster MA. 
Micropulse and continuous wave diode retinal 
photocoagulation: visible and subvisible lesion parameters. 
Br J Ophthalmol. 2006;90(6):709-12. doi: 
10.1136/bjo.2005.086942 pmid: 16531424 
21. Maslin J, Chen P, Sinard N. Comparison of acute 
histopathological changes in human cadaver eyes after 
micropulse and continuous wave trans-scleral 
cyclophotocoagulation.  Poster presented at: The 26th 
Annual AGS Meeting; Lauderdale, FL2016. 
22. Johnstone M, Murray J. Transcleral Laser Induces Aqueous 
Outflow Pathway Motion & Reorganization.  AGS 2017; 
Coronado, CA2017  
23. Stamper RL, Lieberman MF, Drake MV. Becker-Shaffer's 
Diagnosis and Therapy of the Glaucomas: Elsevier Health 
Sciences; 2009. 
24. Emanuel ME, Grover DS, Fellman RL, Godfrey DG, Smith O, 
Butler MR, et al. Micropulse Cyclophotocoagulation: Initial 
Results in Refractory Glaucoma. J Glaucoma. 
2017;26(8):726-9. doi: 10.1097/IJG.0000000000000715 
pmid: 28671927 
25. Williams AL, Moster MR, Rahmatnejad K, Resende AF, 
Horan T, Reynolds M, et al. Clinical Efficacy and Safety 
Profile of Micropulse Transscleral Cyclophotocoagulation in 
Refractory Glaucoma. J Glaucoma. 2018;27(5):445-9. doi: 
10.1097/IJG.0000000000000934 pmid: 29521718 
26. Nguyen M, Noecker M. Micropulse Trans-Scleral 
Cyclophotocoagulation For The Treatment Of Glaucoma.  
Presented at: The 26th Annual AGS Meeting; Coronado, 
CA2017. 
27. Shazly M, Tarek A. Outcomes Of Micropulse Transscleral 
Cyclophotocoagulation In Medically Uncontrolled 
Glaucoma.  Presented at: The 26th Annual AGS Meeting; 
Coronado, CA2017. 
28. Sanchez FG, Lerner F, Sampaolesi J, Noecker R, Becerra N, 
Iribarren G, et al. Efficacy and Safety of Micropulse(R) 
Transscleral Cyclophotocoagulation in Glaucoma. Arch Soc 
Esp Oftalmol. 2018. doi: 10.1016/j.oftal.2018.08.003 pmid: 
30290978 
29. Masi M, Lin SC, Babic K. Micropulse Transscleral Diode Laser 
Cyclophotocoagulation: Mid To Long-Term Results.  
Presented at: The 26th Annual AGS Meeting; Coronado, 
CA2017. 
30. Sanchez F, Lerner F, Sampaolesi J, Noecker R, Becerra N, 
Iribarren G. Success Rate of Micropulse Transscleral 
Cyclophotocoagulation in Complex Glaucoma Based on 
Variable Treatment Duration.  ARVO 2018; Honolulu, 
HI2018. 
31. Radhakrishnan S, Wan J, Tran B. Outcomes Of Micropulse 
Cyclophotocoagulation - A Multicenter Review.  Presented 
at: The 26th Annual AGS Meeting; Coronado, CA2017.
 
 
